|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
ES2680915T3
(es)
*
|
2010-01-28 |
2018-09-11 |
The Children's Hospital Of Philadelphia |
Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
AU2012304993B2
(en)
*
|
2011-09-08 |
2017-09-14 |
Uniqure Ip B.V. |
Removal of contaminating viruses from AAV preparations
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
|
US9644216B2
(en)
|
2013-11-26 |
2017-05-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors for treatment of glycogen storage disease
|
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
CA3276269A1
(en)
|
2014-03-18 |
2026-03-02 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
DK3628334T5
(da)
|
2014-03-21 |
2024-09-02 |
Genzyme Corp |
Genterapi til behandling af retinitis pigmentosa
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
BR112017011217A2
(pt)
*
|
2014-11-28 |
2018-02-06 |
Uniqure Ip B.V. |
impurezas de dna em uma composição compreendendo um vírion parvoviral
|
|
ES2824829T3
(es)
|
2014-12-23 |
2021-05-13 |
Us Health |
Vectores de virus adenoasociado que codifican G6PC modificada y usos de estos
|
|
CN107428799A
(zh)
|
2015-01-13 |
2017-12-01 |
阿尔法韦士曼公司 |
纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
EP3262162A4
(en)
*
|
2015-02-23 |
2018-08-08 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3283126B1
(en)
|
2015-04-16 |
2019-11-06 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
CA2983808C
(en)
|
2015-04-23 |
2022-03-22 |
Washington State University |
Smad7 gene delivery as a therapeutic
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
WO2017100676A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
CA3008142A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
CN109069568B
(zh)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
用于连接dna结合结构域和切割结构域的组合物
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
US12070510B2
(en)
|
2016-02-05 |
2024-08-27 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
ES2896080T3
(es)
*
|
2016-03-31 |
2022-02-23 |
Spark Therapeutics Inc |
Procedimiento en columna totalmente escalable de preparación de VAAr
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
|
KR20190045174A
(ko)
*
|
2016-07-21 |
2019-05-02 |
스파크 테라퓨틱스, 인코포레이티드 |
재조합 아데노신 관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터
|
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
|
|
IL300783B2
(en)
|
2016-08-24 |
2026-03-01 |
Sangamo Therapeutics Inc |
Engineered nucleases with target-specific zinc fingers
|
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics, Inc. |
regulação da expressão gênica usando nucleases manipuladas
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
CN110168081B
(zh)
*
|
2016-11-04 |
2024-08-16 |
武田药品工业株式会社 |
腺相关病毒纯化方法
|
|
EP3321357A1
(en)
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
|
JP2020506695A
(ja)
|
2017-01-30 |
2020-03-05 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
糖原病を処置するための組換えウイルスベクター
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
KR20190118163A
(ko)
|
2017-02-20 |
2019-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
EP3622065A1
(en)
|
2017-05-09 |
2020-03-18 |
Emory University |
Clotting factor variants and their use
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
KR20250030036A
(ko)
|
2017-06-07 |
2025-03-05 |
스파크 테라퓨틱스, 인코포레이티드 |
개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
|
|
SG11201913157RA
(en)
*
|
2017-06-30 |
2020-01-30 |
Spark Therapeutics Inc |
Aav vector column purification methods
|
|
CA3071683A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
IL321310A
(en)
|
2017-10-20 |
2025-08-01 |
Res Inst Nationwide Childrens Hospital |
Methods and materials for NT-3 gene therapy
|
|
CN120505370A
(zh)
*
|
2017-11-08 |
2025-08-19 |
诺华股份有限公司 |
制备病毒载体的手段和方法及其用途
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
AU2019215152A1
(en)
|
2018-02-01 |
2020-08-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
|
|
WO2019156795A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
WO2019169291A1
(en)
|
2018-03-02 |
2019-09-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
|
MA52200A
(fr)
*
|
2018-04-05 |
2021-02-17 |
Nightstarx Ltd |
Compositions de vaa, procédés de préparation et méthodes d'utilisation
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
US12228571B2
(en)
|
2018-06-08 |
2025-02-18 |
Novartis Ag |
Cell-based assay for measuring drug product potency
|
|
CN113528510A
(zh)
|
2018-06-29 |
2021-10-22 |
武汉纽福斯生物科技有限公司 |
治疗遗传性视神经病变的组合物和方法
|
|
CA3109432A1
(en)
|
2018-08-20 |
2020-02-27 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
AU2019389047A1
(en)
*
|
2018-11-30 |
2021-05-20 |
Novartis Ag |
AAV viral vectors and uses thereof
|
|
DK3898981T5
(da)
|
2018-12-18 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme
|
|
SG11202106855YA
(en)
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
MX2021008542A
(es)
*
|
2019-01-18 |
2021-11-12 |
Voyager Therapeutics Inc |
Métodos y sistemas para la producción de partículas de aav.
|
|
MA56393A
(fr)
|
2019-06-28 |
2022-05-04 |
Bayer Healthcare Llc |
Matériels et méthodes de régulation de l'édition de gènes
|
|
AU2020319168B2
(en)
|
2019-07-25 |
2024-02-29 |
Novartis Ag |
Regulatable expression systems
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
EP4090381A1
(en)
|
2020-01-17 |
2022-11-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
<smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies
|
|
KR20220163940A
(ko)
|
2020-02-04 |
2022-12-12 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
항-디니트로페놀 키메라 항원 수용체
|
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
|
CN116096905A
(zh)
|
2020-02-21 |
2023-05-09 |
阿库斯股份有限公司 |
用于治疗人受试者的非年龄相关性听力损伤的组合物和方法
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
JP7526360B2
(ja)
*
|
2020-08-18 |
2024-07-31 |
ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． |
マルチモーダル金属アフィニティー処理ａａｖカプシド
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
EP4229204A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nucleic acid constructs for simultaneous gene activation
|
|
KR20230085929A
(ko)
|
2020-10-15 |
2023-06-14 |
에프. 호프만-라 로슈 아게 |
Va rna 전사를 위한 핵산 구조체
|
|
US20240398985A1
(en)
|
2021-09-16 |
2024-12-05 |
Novartis Ag |
Novel transcription factors
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
|
JP2025517628A
(ja)
|
2022-05-06 |
2025-06-10 |
ノバルティス アーゲー |
新規の組換えａａｖ ｖｐ２融合ポリペプチド
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
EP4532737A1
(en)
|
2022-06-03 |
2025-04-09 |
F. Hoffmann-La Roche AG |
Method for producing recombinant aav particles
|
|
KR20250036743A
(ko)
|
2022-07-14 |
2025-03-14 |
에프. 호프만-라 로슈 아게 |
재조합 aav 입자를 생산하는 방법
|
|
EP4744752A1
(en)
|
2022-09-12 |
2026-05-20 |
Hoffmann La Roche |
METHOD FOR SEPARING SOLID AND EMPTY AAV PARTICLES
|
|
IL322001A
(en)
|
2023-02-07 |
2025-09-01 |
Hoffmann La Roche |
Method for detecting antibodies to anti-AAV particles
|
|
WO2024168358A1
(en)
|
2023-02-10 |
2024-08-15 |
Expression Therapeutics, Llc |
Lentiviral system
|
|
JP2026508221A
(ja)
|
2023-02-22 |
2026-03-10 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
免疫優性ｔ細胞エピトープを欠く組換えアデノ随伴ウイルスベクターおよびその使用
|
|
EP4680243A1
(en)
|
2023-03-17 |
2026-01-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Methods for treatment of age-related macular degeneration
|
|
EP4683676A1
(en)
|
2023-03-21 |
2026-01-28 |
F. Hoffmann-La Roche AG |
Method for the production of recombinant aav particle preparations
|
|
WO2025090942A1
(en)
*
|
2023-10-26 |
2025-05-01 |
University Of Notre Dame Du Lac |
Gene therapy for treatment of neurometabolic disease
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|
|
WO2026022064A1
(en)
|
2024-07-22 |
2026-01-29 |
F. Hoffmann-La Roche Ag |
Novel aav rep orfs and rep polypeptides
|
|
WO2026037757A1
(en)
|
2024-08-13 |
2026-02-19 |
F. Hoffmann-La Roche Ag |
Modified aav particles
|